Chromosomal microarray (CMA) for autism: what it finds and what it misses
A chromosomal microarray finds a cause in roughly 1 in 11 autistic children when it is the only test used — here is what it can and cannot tell you.
The short answer
- A chromosomal microarray (CMA) looks for missing or duplicated stretches of chromosome and finds a genetic cause in about 9.3% of autistic children when it is the only test used, in a 258-child study (Tammimies et al., 2015).
- CMA cannot diagnose autism — no genetic test can — and it misses single-letter DNA changes and most balanced rearrangements (Miller et al., 2010). It also misses the repeat expansion behind fragile X syndrome, which needs its own separate test.
- Every CMA result lands in one of five classes, from pathogenic to benign, and an uncertain result (a VUS) does not predict how your child will grow up (Riggs et al., 2020).
- Genetics guidelines increasingly place exome or genome sequencing before or alongside microarray, because sequencing finds a cause more often across children with broader developmental differences (Srivastava et al., 2019; Manickam et al., 2021).
- A microarray usually needs a blood or saliva sample sent to a lab. Cost, turnaround, and what your insurer requires all vary — ask your genetics team about each before you agree to testing.
If your child is under 5
Ages 0–4- A microarray is often the first genetic test offered at this age, sometimes alongside fragile X testing, because it is well-established and widely available.
- If your child also has feeding difficulty, slow growth, seizures, or a heart or kidney finding, mention this — it can change which test genetics recommends first.
- Action: before the appointment, write down every medical feature besides autism, even ones that seem unrelated, and bring the list.
Changes when you change the age at the top of the page.
If your child is 5 to 8
Ages 5–8- Schools sometimes ask whether genetic testing has happened. A clear answer — done, not done, or in progress — is a complete answer.
- A normal microarray result does not close the door. Ask whether exome sequencing is a reasonable next step.
- Action: if a microarray was done years ago and nothing else since, ask your pediatrician whether it is worth revisiting with newer testing.
Changes when you change the age at the top of the page.
If your child is 9 to 12
Ages 9–12- Your child may ask what the blood draw or saliva kit is for. A short, honest answer — 'it looks for changes in your DNA that might explain some things' — is enough.
- A microarray result rarely changes classroom supports on its own, but it can change which specialists are involved and how often your child is screened.
- Action: ask genetics to put any result and its next-step recommendations in writing, and keep a copy with your child's other records.
Changes when you change the age at the top of the page.
If your child is a teenager
Ages 13–17- Your teenager's own view about testing carries real weight, and increasingly some legal weight as they approach adulthood.
- Autistic people have the right to decide about their own genetic information, including whether they want to know an uncertain result.
- Action: talk with your teenager directly about the test and what you would and would not do with the result, before the appointment.
Changes when you change the age at the top of the page.
What does a chromosomal microarray actually look for?
A chromosomal microarray (CMA) checks your child’s chromosomes for stretches of DNA that are missing (a deletion) or present in an extra copy (a duplication). Geneticists call these copy-number variants, or CNVs. It does not read gene letters one by one.
Losing or duplicating even a modest stretch of chromosome can remove or double up dozens of genes at once, including genes involved in how the brain and body develop. A microarray is built to catch exactly this kind of large-scale change, across the whole genome, in a single test. Single-letter changes within a gene are a different kind of change and need a different test, covered below.
A microarray cannot diagnose autism. No genetic test can. It can sometimes explain part of why your child’s development went the way it did, which is a narrower job.
Why do doctors usually offer a microarray first?
Because it finds a cause far more often than the older test it replaced. That older test, a karyotype, is essentially a low-resolution photograph of the chromosomes that spots only the largest rearrangements. A 2010 consensus statement from the International Standard Cytogenomic Array Consortium, reviewing 33 studies and nearly 22,000 patients, found that chromosomal microarray finds a cause in 15–20% of people with unexplained developmental delay, intellectual disability, or autism — compared with about 3% for a standard karyotype, once well-known chromosomal syndromes like Down syndrome are set aside (Miller et al., 2010). That’s a large enough gap that the consortium recommended replacing karyotype with microarray as the first genetic test for this group of children.
A 2013 guideline from the American College of Medical Genetics and Genomics set out how a geneticist should approach autism specifically: confirm the autism diagnosis first, discuss testing options and their likely yield with the family before ordering anything, and build an evaluation plan around that individual child’s history and features rather than a fixed list (Schaefer & Mendelsohn, 2013). In practice this is why a microarray, often paired with fragile X testing, is what many families are offered first.
How often does a microarray find a cause in autistic children?
About 1 in 11 when it is the only test used. A 2015 study in JAMA tested 258 unrelated autistic children with a microarray and found a molecular cause in 24 of them — 9.3% (95% CI, 6.1–13.5%) (Tammimies et al., 2015). The 15–20% figure above is higher because it comes from a broader group — developmental delay, intellectual disability, and autism combined, including children referred for multiple physical differences (a 2019 meta-analysis cites the same range; Srivastava et al., 2019).
The same study also ran exome sequencing on 95 parent-child trios from that group and found a cause in 8.4% of those, with a combined yield of 15.8% once both tests were used together. Yield was meaningfully higher in children who also had other physical features alongside autism — major congenital differences and minor physical differences, which the study scored for every child — than in children whose only feature was autism itself.
Put together, the honest range a parent should hear is: about 1 in 11 (9.3%) across a whole clinic group of autistic children, lower for a child whose only feature is autism and higher for a child with other physical features alongside it, and about 1 in 6 (15.8%) when a microarray and exome sequencing are used together (Tammimies et al., 2015).
Ask your genetics team directly what is and isn’t known about any specific change found in your child — that detail matters more to your family than the general statistic above.
What can a normal microarray result still leave undetected?
A lot. A microarray is powerful for large deletions and duplications, and cannot see several other kinds of genetic change that also cause autism and related conditions:
- Single-letter changes. A typo within a gene — one DNA letter swapped, added, or dropped — is invisible to a microarray. This is what exome or genome sequencing is built to catch, and it’s a large part of why sequencing finds a cause more often overall.
- Fragile X and other repeat expansions. Fragile X syndrome is caused by an expanded repeat within one gene, not a missing or duplicated chunk of chromosome. A microarray does not reliably detect it. Fragile X needs its own dedicated test — read more on the fragile X page.
- Balanced rearrangements. Sometimes a piece of chromosome moves to a new location, or two chromosomes swap segments, without any DNA actually being lost or gained. Because nothing is missing or duplicated, a microarray usually can’t see it, even though the rearrangement occasionally still causes problems by landing in the middle of an important gene. The 2010 consensus statement notes that these, along with low-level mosaicism, are real but relatively infrequent causes of the pattern a microarray is used to investigate — under 1% (Miller et al., 2010).
- Most regulatory DNA. Much of the genome doesn’t code for a protein directly but still controls when and how much of a gene gets used. A microarray can see a deletion or duplication that removes a stretch of this DNA, but neither a microarray nor exome sequencing reads single-letter changes in it. Only whole genome sequencing reads this DNA in any detail, and even then interpretation is still developing.
None of this means a microarray is a weak test — it does its specific job well. It means a normal microarray result answers one question and leaves several others open.
A microarray can also occasionally turn up something you weren’t looking for. A SNP-based microarray can show long stretches where both copies of a chromosome match unusually closely, which can point to related parents or to both copies of a chromosome coming from one parent rather than one from each. It can also, on rare occasion, flag a change linked to a condition that shows up in adulthood rather than childhood. Ask the lab up front what kinds of findings they report beyond the reason you tested, and what you can choose not to receive.
What do the five microarray result classes mean?
Every CNV a microarray finds is sorted into one of five categories, under a joint standard from the American College of Medical Genetics and Genomics and the Clinical Genome Resource (Riggs et al., 2020):
- Pathogenic — strong evidence this specific change causes the condition it’s associated with.
- Likely pathogenic — evidence points the same direction, but isn’t yet as strong.
- Uncertain significance (a variant of uncertain significance, or VUS) — not enough evidence yet to call it either way. This is common, not a diagnosis, and not necessarily worrying.
- Likely benign — evidence suggests this change doesn’t cause problems.
- Benign — this change is well-documented as a normal variation, no different from the countless small differences everyone’s DNA carries.
The 2020 standard also makes a point worth repeating to any clinician who hands you a result without context: classifying a variant is meant to reflect the evidence about that variant itself, deliberately separated from any prediction about what it means for your specific child’s future (Riggs et al., 2020). A VUS, or even a likely pathogenic result, is not a forecast. It’s a starting point for a conversation. A full walkthrough of what each class means for next steps is on the genetic testing results page.
Does exome sequencing replace a microarray or follow it?
Increasingly it comes first or alongside, though practice is uneven. A 2019 meta-analysis and multidisciplinary consensus statement found that exome sequencing finds a cause in 36% of children with a neurodevelopmental difference — a group the authors define as global developmental delay, intellectual disability, and autism — markedly more than the 15–20% reported for microarray. The figure was 31% when the developmental difference was the only finding and 53% when other conditions were present. The authors proposed exome sequencing as the new first-tier test for this group (Srivastava et al., 2019). A 2021 evidence-based guideline from the American College of Medical Genetics and Genomics made a formal recommendation: exome or genome sequencing should be considered as a first- or second-tier test for children with congenital anomalies, developmental delay, or intellectual disability (Manickam et al., 2021).
Some clinics now start with sequencing. Others still start with a microarray, often because it’s faster to authorize with insurance or more established in their workflow, and add sequencing later if the microarray doesn’t explain enough. Neither order is wrong. What matters is that you know which test has been done, which has not, and what each can find. The full comparison, including what a whole exome sequencing result can add, is on the whole exome sequencing page; the genetic testing overview walks through the whole decision from the start.
Sample, turnaround, and cost
A microarray is usually run from a blood draw, though some labs offer a saliva or cheek-swab kit, which can be easier for a young child. Turnaround varies by lab. Ask at the appointment when you should expect to hear and who to call if that date passes; if no one gave you a date, call the ordering clinic rather than waiting.
Cost and insurance coverage vary widely by state, plan, and lab, and we won’t guess at a number here. What consistently helps: ask your clinician for a letter of medical necessity before the test is ordered, and ask your insurer directly what a microarray costs under your plan. The genetic testing cost page walks through what to ask and how to plan for it.
Questions to ask genetics about a microarray result
- What specific copy-number variant did you find, if any, and what class is it — pathogenic, likely pathogenic, uncertain, likely benign, or benign?
- Has fragile X been tested separately, or only ruled out by inference?
- Given this result, would you recommend exome or genome sequencing next — and why or why not?
- If the result is a VUS, what would change the classification, and is re-analysis planned as more is learned?
- Does this result suggest a specific screening schedule for anything besides autism — heart, kidney, hearing, vision, seizures?
- Should other family members be tested, and what would a positive or negative result in a parent mean for future children?
Write the answers down. You will be asked the same questions again by the next specialist, the school, or your own memory at 2am.
Questions parents ask after reading this
- Our geneticist mentioned “first-tier” and “second-tier” tests — what do those terms actually mean for what happens to our child next?
- The result mentions a duplication no one has explained clearly. What do we do with that?
- Is it worth paying out of pocket for exome sequencing if the microarray found nothing?
- Our clinician wants to test us as parents too. Why, and do we have to?
Bring this list to your next genetics appointment. A specific question gets a specific, useful answer; a vague one usually doesn’t.
If you only do three things
- Ask directly whether fragile X testing has been done separately — a microarray does not cover it.
- If your result includes a VUS or any variant you don’t fully understand, ask genetics to explain it in one plain sentence, and write that sentence down.
- Keep a copy of the result and its lab report somewhere you and your pediatrician can both find again — you will be asked for it more than once.
A microarray answers one specific, useful question. It was never meant to answer all of them.
Questions parents ask
Written by Josh Kay · Reviewed by the ActNowASD editorial team · · How we check numbers →
Where this comes from
- Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. American Journal of Human Genetics. 2010pubmed.ncbi.nlm.nih.gov
- Riggs ER, Andersen EF, Cherry AM, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genetics in Medicine. 2020pubmed.ncbi.nlm.nih.gov
- Tammimies K, Marshall CR, Walker S, et al. Molecular Diagnostic Yield of Chromosomal Microarray Analysis and Whole-Exome Sequencing in Children With Autism Spectrum Disorder. JAMA. 2015pubmed.ncbi.nlm.nih.gov
- Srivastava S, Love-Nichols JA, Dies KA, et al. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. Genetics in Medicine. 2019pubmed.ncbi.nlm.nih.gov
- Manickam K, McClain MR, Demmer LA, et al. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine. 2021pubmed.ncbi.nlm.nih.gov
- Schaefer GB, Mendelsohn NJ; Professional Practice and Guidelines Committee. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. Genetics in Medicine. 2013pubmed.ncbi.nlm.nih.gov
This is health information, not medical advice. It cannot replace a conversation with your child's doctor.